THIS SESSION IS JOINTLY SPONSORED WITH AABB
Despite the therapeutic benefits of transfusions, some patients develop antibodies against antigens on the transfused product, causing life-threatening transfusion reactions and transfusion refractoriness. This session will review recent advances in our understanding of host immune responses that result in transfusion alloimmunization and discuss how this knowledge can help identify biomarkers to predict in advance which patients will develop alloantibodies and potential therapeutic strategies to avert alloimmunization.
Dr. Jeanne Hendrickson will review potential triggers for red blood cell alloimmunization in humans and mice, taking donor and recipient factors into consideration.
Dr. James Zimring will review genetic and acquired host-related factors that can influence alloimmunization and discuss the use of several novel transfusion models to uncover cellular immune responses to transfused red blood cell products that result in alloimmunization.
Dr. Karina Yazdanbakhsh will review cellular immune responses in chronically transfused patients with sickle cell disease, and discuss the role of hemolysis in sickle cell alloimmunization and novel strategies to reduce the risk of this complication.